Department of Hepato-Gastroenterology and Digestive Oncology, Robert-Debré University Hospital, Reims, France.
Neuroendocrinology. 2017;105(4):412-425. doi: 10.1159/000475527. Epub 2017 Aug 12.
Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) are a heterogeneous subgroup of rare neoplasms that represent about a third of all poorly differentiated neuroendocrine carcinomas (PDNEC). MiNEN combine a neuroendocrine component, usually a PDNEC, and a non-neuroendocrine component, generally an adenocarcinoma, both accounting for at least 30% of the neoplasm. MiNEN are classified as high-, intermediate-, or low-grade malignancies depending on the metastatic potential of the tumour components. High-grade malignant component should be considered even if it represents <30% of the tumour. The prognosis of MiNEN is generally intermediate between those of the two "pure" components composing it. The aim of this comprehensive review of the literature is to suggest a standardized management of MiNEN. An increasing body of evidence suggests that PDNEC components share molecular abnormalities with their adenocarcinoma counterparts, but also display additional alterations. This advocates for a common origin, and that the presence of a PDNEC component in an adenocarcinoma could indicate a turning point in carcinogenesis.
混合性神经内分泌-非神经内分泌肿瘤(MiNEN)是一组罕见肿瘤的异质性亚组,占所有低分化神经内分泌癌(PDNEC)的约三分之一。MiNEN 结合了神经内分泌成分,通常是 PDNEC,和非神经内分泌成分,通常是腺癌,两者至少占肿瘤的 30%。MiNEN 根据肿瘤成分的转移潜能分为高、中、低级别恶性肿瘤。即使高级别恶性成分仅占肿瘤的<30%,也应予以考虑。MiNEN 的预后通常介于组成它的两个“纯”成分之间。本次对文献的全面综述旨在提出 MiNEN 的标准化管理建议。越来越多的证据表明,PDNEC 成分与腺癌成分具有相同的分子异常,但也表现出其他改变。这支持了共同起源的观点,即腺癌中存在 PDNEC 成分可能表明致癌作用的转折点。